Drug Topics

DECEMBER 1, 2023

A new study found that glucose monitoring devices can help significantly improve the sleep of both parents and children.

201

201

STAT

DECEMBER 1, 2023

In Ukraine, a little bit of good news can go a long way, and the lifesaving work being done as a result of the President’s Emergency Plan for AIDS Relief (PEPFAR) has been a rare but reliable source of good news. That’s why the U.S. Congress’ delay in reauthorizing this program has been so difficult to hear about. Much has been written about the impact of PEPFAR since its inception in 2003.

144

144

Pharmacy Times

DECEMBER 1, 2023

Non-expansion states had an increase in prescriptions after PA removal at 27.3% and Medicaid expansion states demonstrated a 22% decrease in prescriptions.

139

139

STAT

DECEMBER 1, 2023

When Jennifer Case was living in Los Angeles in her early 30s, she was hospitalized 11 times. She had been born with two rare heart abnormalities, Ebstein anomaly and Wolff-Parkinson-White syndrome. Her parents were told that she probably wouldn’t live.

Hospitals 137

Hospitals 137

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

DECEMBER 1, 2023

Although involvement of a cardiologist for heart failure has been associated with reduced rates of in-hospital mortality, not all patients see a cardiologist when hospitalized, according to the investigators.

Hospitals 123

Hospitals 123

STAT

DECEMBER 1, 2023

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications. The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said.

134

134

STAT

DECEMBER 1, 2023

Children with drug-resistant epilepsy who are Black or insured through Medicaid may be less likely than white and privately insured patients to receive surgical treatments that can end or minimize their seizures and extend their lives, according to new research being presented Monday at the American Epilepsy Society’s annual meeting in Orlando, Fla.

Insurance 131

Insurance Hospitals 131

Pharmacy Times

DECEMBER 1, 2023

Investigators believe lowering cholesteryl ester levels could help prevent brain damage and behavioral changes, reducing the risk of Alzheimer disease.

132

132

STAT

DECEMBER 1, 2023

After weeks of anticipation, the U.S. Supreme Court on Monday will hear arguments to decide the fate of a controversial bankruptcy deal in which the owners of Purdue Pharma would contribute up to $6 billion in exchange for immunity from further lawsuits. The company was accused of downplaying the risks of OxyContin and improperly persuading physicians to prescribe the addictive painkiller.

Immunization 129

Immunization 129

Pharmacy Times

DECEMBER 1, 2023

Further research of these mechanisms could be significant in developing future strategies to disrupt the viral persistence in individuals living with HIV.

130

130

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

DECEMBER 1, 2023

One of the hardest parts about getting an X-ray or a CT scan is the wait. Sometimes it takes days, or even weeks, for medical imaging results to be analyzed by a radiologist, transferred to a primary doctor, and then delivered to the patient — good news or bad. Today, that hand-wringing delay has been nearly eliminated. In 2021, provisions from the 21st Century Cures Act kicked in that require health centers to provide patients with access to their health information on request — i

115

115

Pharmacy Times

DECEMBER 1, 2023

Many workers don’t advertise their level of loneliness, nor do they know the impact of loneliness on their well-being.

145

145

PharmExec

DECEMBER 1, 2023

Artificial intelligence is making it quicker to get drug candidates to the clinic, but it isn’t addressing the fundamental need to marry the right candidate and the right target to the right disease.

115

115

Pharmacy Times

DECEMBER 1, 2023

Patients with this genetic variant have impaired neuronal excitability, a trait that has been linked to malfunctional synapses.

139

139

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

DECEMBER 1, 2023

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Today we talk about Pfizer’s obesity woes, how J&J is leaning heavily into artificial intelligence, chat about how ADCs are having a heyday, and ponder the zombie microcap.

FDA 115

FDA 115

Pharmacy Times

DECEMBER 1, 2023

Iberzaplstat was non-inferior to standard of care vancomycin, was safe and tolerable, and will advance into a phase 3 trial.

132

132

European Pharmaceutical Review

DECEMBER 1, 2023

AbbVie has agreed to acquire ImmunoGen and its first-in-class antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx), for a total of approximately $10.1 billion. The antibody-drug conjugate is the first to be approved for platinum-resistant ovarian cancer (PROC) and show meaningful survival benefit for this form of the disease. As a folate receptor alpha (FRα) with a maytansinoid payload DM4, a potent tubulin inhibitor, the biologic medicine offers expansion opportunities in e

FDA 111

FDA 111

Fierce Pharma

DECEMBER 1, 2023

Turkish authorities have launched an investigation into 19 pharmaceutical companies to probe whether their operations violated the country’s competition law, the Turkish Competition Authority discl | The companies, which include Pfizer, J&J, Sanofi, AbbVie, AstraZeneca, Merck and others are being probed for potentially violating Turkish competition law, according to a release from the country's government.

Pharmaceutical Companies 110

Pharmaceutical Companies Pharmaceutical Companies 110

Pharmaceutical Commerce

DECEMBER 1, 2023

In clinical trials, Keytruda plus Padcev lowered the risk of disease progression or death by 55% compared with chemotherapy in adult patients with locally advanced or metastatic urothelial carcinoma.

Chemotherapy 110

Chemotherapy FDA 110

Pharmacy Times

DECEMBER 1, 2023

Following acoustic stimulation intervention, many patients experienced a reduction in neurobehavioral symptoms.

132

132

The Checkup by Singlecare

DECEMBER 1, 2023

For people with Type 2 diabetes, Ozempic is a game-changer: This FDA-approved drug not only lowers blood sugar but can also help people lose weight. Lower blood sugar and weight loss can lead to better health and wellness outcomes for people with diabetes, who are at a higher risk for heart disease, stroke, kidney failure, and vision loss. One of the ways Ozempic (semaglutide) and other GLP-1 receptor agonists work is by decreasing appetite.

Packaging 105

Packaging Compounding FDA 105

Pharmacy Times

DECEMBER 1, 2023

Marlo Blazer, PharmD, BCOP, discusses the collaborative nature of the pharmacist's role within the oncology care team.

122

122

Fierce Healthcare

DECEMBER 1, 2023

Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, retailers and other industry players look to expand their businesses and gain a competitive edge. | A $10 billion Missouri health system merger, Virgin Pulse and HealthComp's $3 billion combination and more merger and acquisition news from the month of November.

105

105

Fierce Pharma

DECEMBER 1, 2023

After a hard-fought battle for FDA approval, AstraZeneca has hit another setback on its quest to turn its potassium-reduction drug Lokelma into a blockbuster. | AstraZeneca has put the kibosh on two late-stage Lokelma trials testing the hyperkalemia drug in patients with heart and kidney diseases. The studies were called off due to “substantially increased enrollment times and low event rates,” AZ said Friday.

FDA 105

FDA 105

pharmaphorum

DECEMBER 1, 2023

AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disease. The STABILIZE-CKD and DIALIZE-Outcomes studies – part of AZ’s CRYSTALIZE programme for the drug – have been shelved because patients were being enrolled into them more slowly than hoped for, and clinical events were occurring at a lower rate than expected.

Labelling 104

Labelling 104

Fierce Pharma

DECEMBER 1, 2023

In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. | In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. The list comprises 10 trailblazers changing the leadership landscape in pharma, biotech and medtech.

105

105

Drug Topics

DECEMBER 1, 2023

The risks of poor health, more health care needs, and gynecological cancer are significantly increased in patients with disabilities.

98

98

STAT

DECEMBER 1, 2023

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.   That’s right.  Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

102

102

Board Vitals - Pharmacist

DECEMBER 1, 2023

With 2024 rapidly approaching, there comes the question of New Year’s Resolutions. Are they to be made or ignored? Many physicians use them to refocus their efforts on meaningful initiatives. Under the guise of a new year’s resolution, some clinicians take the opportunity to remind influencers and stakeholders of efforts that need to be redoubled for the benefit of patients and patient care.

Communication 98

Communication Patient Care Documentation Insurance 98

STAT

DECEMBER 1, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET. After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

101

101

Fierce Pharma

DECEMBER 1, 2023

Texas attorney general Ken Paxton is going after Pfizer—again. | Texas attorney general Ken Paxton is going after Pfizer—again. Less than two weeks after documents were unsealed showing that Texas has accused Pfizer and manufacturer Tris Pharma of providing a compromised ADHD medicine to the state, Paxton has sued Pfizer for “unlawfully misrepresenting the effectiveness” of the company’s COVID-19 vaccine.

Vaccines 98

Vaccines Documentation 98

STAT

DECEMBER 1, 2023

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to promenade with the official mascots, tidy up the leafy grounds, and maybe have a listening party with Mrs. Pharmalot. The rotation will likely include this , this , this and this.

Hospitals 100

Hospitals 100

The Checkup by Singlecare

DECEMBER 1, 2023

Also known as scapulae , the shoulder blades are large triangle-shaped bones in the upper back. When connected with the head of the humerus (the upper arm bone), they create a ball-and-joint socket. Each scapula, which is attached to many muscles and ligaments, moves to keep the shoulder joint in normal alignment as you move your arm. Since you can’t see them, you may not give much thought to your shoulder blades until something goes wrong.

98

98

Drug Store News

DECEMBER 1, 2023

Workflow Services' comprehensive tech platform's data collection and transmission aims to inform public health officials and accelerate care delivery in pharmacy settings.

FDA 96

FDA 96